CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology on 28 may announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). CytRx Corporation (NASDAQ:CYTR) stock opened today at $4.75 and is currently trading at $4.67. The stock showed a positive weekly performance of 13.94%.
On June 9, 2014, the Company held the Annual Meeting of Shareholders of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN). On the record date for the Annual Meeting, there were 176,641,135 shares of Company common stock issued, outstanding and entitled to vote. Shareholders holding 127,610,264 shares of Company common stock were present at the Annual Meeting, in person or represented by proxy. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) stock opened at $0.90, in current trading session and currently is at $0.891, by losing -0.16%. The 52 week range of $0.36 – $1.85. Company’s market capitalization is 158.60 million.
Of late, there has been a lot said and talked about MannKind Corporation (NASDAQ:MNKD) and its diabetes inhaler drug- AFREZZA. This is used to treat type 1 and type 2 diabetes and the drug is currently under consideration for the FDA approval after the regulator had rejected it 2 times around. Very recently, the company got a very positive recommendation for its approval from the key FDA advisory-panel, which can help in clearing its path for a potential approval from the FDA in its final decision that is slated for 15 July. MannKind Corporation (NASDAQ:MNKD) stock is currently trading at $10.17. The EPS of the stock is -0.63. Company’s market capitalization is 3.95 billion.
Galena Biopharma Inc. (NASDAQ:GALE) on June 3 announced updated interim results of a Phase 2 study (Study 102) evaluating GS-9973, its investigational oral inhibitor of spleen tyrosine kinase (Syk), for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). Galena Biopharma Inc. (NASDAQ:GALE) stock opened the session at $3.13, and now is at $3.33. The 52 week range of the Galena Biopharma Inc. (NASDAQ:GALE) stock remained $1.65 – $7.77 and the day range was $2.92 – $3.33.
Inovio Pharmaceuticals Inc. (NYSEMKT:INO) clarified that a third party article published on June 10, 2014, was misrepresentative of facts and can only be taken as malicious. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) stock opened today at $9.94 and is currently trading at $9.83. The stock showed a positive weekly performance of 2.41%.
Leave a Reply